CAI vs NWSA · rev $812.0M vs rev $9.03B
Caris Life Sciences, Inc. Common Stock (CAI) versus NWSA (NWSA) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
NWSA (NWSA) common stock.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported NWSA revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 328.1% from 2025-06-30 to 2026-06-30. NWSA currently screens at market cap $0.
CAI currently screens at market cap $5.22B. NWSA currently screens at market cap $0.
Not investment advice. Open the CAI and NWSA stock pages for the full models.
Not investment advice.